-
Mashup Score: 18
Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma1 In the pivotal KarMMa trial, the majority (72%) of patients achieved rapid, deep and durable responses1 Safety profile of Abecma is well-established and predictable including cytokine release syndrome and neurologic toxicities that are…
Source: news.bms.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 17
Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma1 In the pivotal KarMMa trial, the majority (72%) of patients achieved rapid, deep and durable responses1 Safety profile of Abecma is well-established and predictable including cytokine release syndrome and neurologic toxicities that are…
Source: news.bms.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Huge news!! Bristol Myers Squibb - U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma https://t.co/4GG5oILRfs
-
Bristol Myers Squibb - U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma #mmsm https://t.co/XtgWVFixTB
-
-
Mashup Score: 1
FDA set a target action date of March 27, 2021 Ide-cel is the first CAR T cell therapy accepted for regulatory review for multiple myeloma Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc . (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review their Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121),…
Source: news.bms.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Bristol Myers Squibb - U.S. Food and Drug Administration (FDA) Accepts for priority review Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) #mmsm @NoopurRajeMD #nikhilmunshi @adamssperling https://t.co/PXGHbhz0tI
-
-
Mashup Score: 10
First Phase 3 data to be reported from a trial evaluating an anti-LAG-3 antibody Relatlimab is the company’s third distinct checkpoint inhibitor to demonstrate a benefit for patients Bristol Myers Squibb (NYSE: BMY) today announced primary results from the Phase 2/3 RELATIVITY-047 (CA224-047) trial evaluating the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and Opdivo (nivolumab)…
Source: news.bms.comCategories: Hem/Oncs, Latest HeadlinesTweet-
LAG3 is an immune checkpoint expressed on T cell (including Treg). It has been targeted in a spectrum of cancers. It now looks like a legitimate target requiring more urgent investigation. We await the results. https://t.co/lCL6VY5uta
-
-
Mashup Score: 10
First Phase 3 data to be reported from a trial evaluating an anti-LAG-3 antibody Relatlimab is the company’s third distinct checkpoint inhibitor to demonstrate a benefit for patients Bristol Myers Squibb (NYSE: BMY) today announced primary results from the Phase 2/3 RELATIVITY-047 (CA224-047) trial evaluating the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and Opdivo (nivolumab)…
Source: news.bms.comCategories: Hem/Oncs, Latest HeadlinesTweet-
🚨⭐️RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab +nivolumab In Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary Endpoint of PFS cc’ @HTawbi_MD @OncoAlert https://t.co/yzEPyGxYIb
-
-
Mashup Score: 3
First Phase 3 data to be reported from a trial evaluating an anti-LAG-3 antibody Relatlimab is the company’s third distinct checkpoint inhibitor to demonstrate a benefit for patients Bristol Myers Squibb (NYSE: BMY) today announced primary results from the Phase 2/3 RELATIVITY-047 (CA224-047) trial evaluating the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and Opdivo (nivolumab)…
Source: news.bms.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
$BMY’s anti-LAG3 hits in melanoma. Immunotherapy. https://t.co/oHCAetP0Qf
-
-
Mashup Score: 0
U.S. FDA has assigned a target action date of January 28, 2022 Application based on results from the Phase 3 EXPLORER-HCM trial Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for mavacamten, an investigational, novel, oral, allosteric modulator of cardiac myosin, for patients with symptomatic…
Source: news.bms.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Bristol Myers Squibb - U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb’s Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) https://t.co/C2sb7utUNF
-
-
Mashup Score: 14
Recommendation based on the Phase 3 CheckMate -9ER trial, in which Opdivo in combination with Cabometyx doubled progression-free survival and significantly improved overall survival and response rates Opdivo in combination with Cabometyx showed consistent efficacy benefits across key subgroups of patients Opdivo in combination with Cabometyx also demonstrated a manageable safety profile, with a…
Source: news.bms.comCategories: Latest Headlines, UrologyTweet-
A positive CHMP decision for cabozantinib/nivolumab in metastatic renal cancer. The 40mg dose is attractive for tolerability and the RR, PFS and OS underpins this as an attractive option for these patients. It will be available in the EU soon IMO. https://t.co/w2pcvb91QV
-
-
Mashup Score: 0
In CheckMate -9ER, OPDIVO in combination with CABOMETYX doubled median progression-free survival and objective response rate and showed superior overall survival vs. sunitinib1 Approved across all International Metastatic Renal Cell Carcinoma Database Consortium risk categories1,2 Approval expands Company’s presence in first-line advanced renal cell carcinoma, which includes OPDIVO + YERVOY as a…
Source: news.bms.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Congratulations to @DrChoueiri & team for spearheading this 👉🏼U.S. FDA Approves OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma @OncoAlert https://t.co/0Q80Izxyyg
-
-
Mashup Score: 1Bristol Myers Squibb Statement on Opdivo (nivolumab) Small Cell Lung Cancer U.S. Indication - 5 year(s) ago
In 2018, Opdivo (nivolumab) was granted accelerated approval by the U.S. Food Drug Administration (FDA) for the treatment of patients with small cell lung cancer (SCLC) whose disease has progressed after platinum-based chemotherapy and at least one other line of therapy. The accelerated approval was based on Opdivo’s effect on surrogate endpoints from the Phase 1/2 CheckMate -032 trial of…
Source: news.bms.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#OncoAlert BMS withdraws indication of 3L nivolumab for #SCLC. Durable responses in CM-032 led to FDA accelerated approval but the randomized confirmatory phase III studies were negative: CM331 (2nd line vs topo) and CM451 (maintenance vs placebo) #LCSM https://t.co/nd8qcQ5su5
-
Breaking News: lde-cel (Abecma; idecabtagene vicleucel), approved by FDA for multiple myeloma. This is the first CAR-T therapy for myeloma. Many patients have been waiting for this good news. @agarwalonc @BMS_Myeloma_US @bluebirdbio https://t.co/gDrbXYu3RG